NEW YORK and HAIKOU, China, Aug. 1 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. (''China Pharma'') (OTC Bulletin Board: CPHI) which develops, manufactures, and markets leading off-patent brand and newly developed products in China, today announced the Company will host an earning conference call at 10:00 a.m. EDT on Wednesday, August 6, 2008 to discuss these results. The Company also plans to release its earnings earlier that same day.
Ms. Zhilin Li, President and CEO of China Pharma Holdings, Inc., Mr. Xinhua Wu, Chief Financial Officer, and Mr. Alan Sheinwald, Partner of HC International will be hosting the call. To participate in the conference call, please dial 1-800-591-6945 ten minutes prior to the scheduled conference call time. International callers should dial 1-617-614-4911. The conference pass code is 11374834.
If you are unable to participate in the call at this time, a replay will be available on Wednesday, August 6 at 12:00 p.m. EDT, through Wednesday, August 13. To access the replay, please dial 1-888-286-8010. International callers should dial 1-617-801-6888. The conference pass code is 77875355. This conference call will be broadcast live over the Internet and can be accessed by clicking this link: http://phx.corporate-ir.net/playerlink.zhtml?c=145098&s=wm&e=1914439 . A replay will also be available shortly after the call on China Pharma' website http://www.chinapharmaholdings.com .
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets leading off-patend brand and newly developed products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular, cerebrovascular, CNS, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement:
Certain statements in this press release and oral statements made by
China Pharma on its conference call in relation to this release, constitute
forward-looking statements for purposes of the safe harbor provisions under
The Private Securities Litigation Reform Act of 1995. Any statements set
forth above that are not historical facts are forward-looking statements
that involve risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements, which may
include, but are not limited to, such factors as unanticipated changes in
product demand, increased competition, failure to obtain or maintain
intellectual property protection, downturns in the Chinese economy,
uncompetitive levels of research and development, failure to obtain
regulatory approvals, and other information detailed from time to time in
the Company's filings and future filings with the United States Securities
and Exchange Commission. The forward-looking statements made herein speak
only as of the date of this press release and the Company undertakes no
duty to update any forward-looking statement to conform the statement to
actual results or changes in the company's expectations.
For more information, please contact:
China Pharma Holdings, Inc.
HC International, Inc.
|SOURCE China Pharma Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved